Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Study ID
NCT04906993
Phase
PHASE3
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a randomized, open-label, controlled, multi-center Phase III clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer. All enrolled patients will be randomly divided into 2 groups and continuously treated until any event that meets the criteria for end of the clinical trial.

Key Dates

Start date
Jul 23, 2021
Status verified
Sep 2025
Primary completion
Jun 10, 2025
Completion
May 31, 2027

Study Design

Enrollment
443 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: camrelizumab combined with famitinib malate
  • Active Comparator: platinum-based chemotherapy

Primary Outcome Measure

Progression-free survival (PFS) assessed by the BIRC based on RECIST V1.1 criteria [ Time Frame: up to 2 years ]

Related Studies